Key Takeaways
- • HarbourVest has closed its 13th US flagship fund at $2.4bn, according to PEI Private Equity reporting by David Bogoslaw.
- • Roughly $1.3bn of the fund's commitments are earmarked for venture capital, with most going to managers HarbourVest has longstanding relationships with.
- • The venture allocation also backs emerging managers spinning out of brand-name firms with strong track records.
- • The fund's venture activity spans deep tech and healthcare/life sciences themes, per the article's sector tags.
Summary
HarbourVest has raised $2.4bn for its 13th US flagship fund, according to PEI Private Equity. The report, written by David Bogoslaw and published on 6 May 2026, frames the close as a significant commitment from limited partners to the Boston-based manager's US flagship programme.
About $1.3bn of the total is committed to venture capital strategies. According to the article, the majority of these venture commitments go to firms with which HarbourVest has longstanding relationships. The firm is also backing emerging managers who are spinning out of brand-name firms with strong track records, a approach that broadens its manager pool while leveraging established performance histories.
The article's coverage tags point to deep tech and healthcare/life sciences as areas of focus within the venture allocation. The primary source does not provide further breakdown of the remaining capital allocation beyond the venture commitments, and no additional fund-level detail such as target size or fee terms is reported in the material reviewed.
About $1.3bn of the total is committed to venture capital strategies. According to the article, the majority of these venture commitments go to firms with which HarbourVest has longstanding relationships. The firm is also backing emerging managers who are spinning out of brand-name firms with strong track records, a approach that broadens its manager pool while leveraging established performance histories.
The article's coverage tags point to deep tech and healthcare/life sciences as areas of focus within the venture allocation. The primary source does not provide further breakdown of the remaining capital allocation beyond the venture commitments, and no additional fund-level detail such as target size or fee terms is reported in the material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.